From Wikipedia, the free encyclopedia
Chemical compound
TS-121 (THY1773 ) is an
orally active ,
selective
vasopressin
V1B receptor
antagonist which is under development by
Taisho Pharmaceutical for the
adjunctive treatment of
major depressive disorder .
[1]
[2]
[3] As of May 2017, it is in
phase II
clinical trials for this indication.
[1]
[2]
[4]
See also
References
^
a
b
"TS 121 -" . AdisInsight . Springer Nature Switzerland AG.
^
a
b
"New Drug Pipeline - Taisho Pharmaceutical Holdings" .
^ Kamiya M, Sabia HD, Marella J, Fava M, Nemeroff CB, Umeuchi H, Iijima M, Chaki S, Nishino I (September 2020).
"Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study" . Journal of Psychiatric Research . 128 : 43–51.
doi :
10.1016/j.jpsychires.2020.05.017 .
PMID
32521250 .
S2CID
219587135 .
^ Inatani S, Mizuno-Yasuhira A, Kamiya M, Nishino I, Sabia HD, Endo H (May 2021).
"Prediction of a clinically effective dose of THY1773, a novel V1B receptor antagonist, based on preclinical data" . Biopharmaceutics & Drug Disposition . 42 (5): 204–217.
doi :
10.1002/bdd.2273 .
PMC
8252455 .
PMID
33734452 .
External links
Clinical trial number
NCT03093025 for "A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder" at
ClinicalTrials.gov